טיגציל

País: Israel

Idioma: hebreo

Fuente: Ministry of Health

Ingredientes activos:

TIGECYCLINE

Disponible desde:

PFIZER PFE PHARMACEUTICALS ISRAEL LTD

Código ATC:

J01AA12

formulario farmacéutico:

אבקה להכנת תמיסה לאינפוזיה

Composición:

TIGECYCLINE 50 MG/DOSE

Vía de administración:

תוך-ורידי

tipo de receta:

מרשם נדרש

Fabricado por:

PFIZER INC, USA

Grupo terapéutico:

TIGECYCLINE

Área terapéutica:

TIGECYCLINE

indicaciones terapéuticas:

TYGACIL is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:Complicated Skin and Skin Structure Infections:Complicated skin and skin structure infections caused by Escherichia coli, Enterococcus faecalis (vancomycin-susceptible isolates ), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus agalactiae, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Streptococcus pyogenes, Enterobacter cloacae, Klebsiella pneumoniae, and Bacteroides fragilis .Complicated Intra-abdominal Infections:Complicated intra-abdominal infections caused by Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, Enterococcus faecalis (vancomycin-susceptible isolates), Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus anginosus grp. (includes S. anginosu

Fecha de autorización:

2022-02-28